Though the use of MEK inhibitors as single-agent therapy in colorectal cancer is not supported by these results, a recent phase II study of a MEK inhibitor combined with irinotecan in KRAS mutant CRC yielded interesting results worthy of further study (Hochster et al., 2015). This evidence concerns the gene KRAS and colorectal cancer.